21:35 , Feb 24, 2017 |  BC Week In Review  |  Financial News

TxCell completes private placement

On Feb. 22, immunotherapy company TxCell S.A. (Euronext:TXCL) raised €11 million ($11.7 million) through the sale of 5.5 million shares at €2 in a private placement. Investors also received one-year warrants to purchase shares at...
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Nomura's investments

Nomura's investments Nomura's investments Nomura Phase4 Ventures has invested in at least 25 biotechs since 1999. Usually Nomura's contribution for an initial investment will be some $15-$25 million of the round, although in subsequent rounds...
08:00 , Dec 4, 2006 |  BioCentury  |  Politics, Policy & Law

Expanding the French model

French efforts to put state-backed capital into innovator companies look to be gaining legs, as the European Commission has opened the door for funding schemes that could be copied in other EU countries. Last month,...
08:00 , Jan 24, 2005 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Mutabilis S.A. Paris, France Technology: Antivirulence for prevention of severe infection Disease focus: Infectious Clinical status: Research Founded: 2001 by Xavier Nassif University collaborators: University of Medicine Necker, Ecole Normale Superiore Corporate partners: 4SC AG...
08:00 , Jan 3, 2005 |  BioCentury  |  Finance

European VC leads

European VC leads Firm Base # of Leads TVM Techno Venture Germany, U.S. 5 Management Innoven Partners France 3 Atlas Venture Europe, U.S. 2 Auriga Ventures France 2 Austria Wirtschaftsservice Austria 2 Avlar BioVentures U.K....
07:00 , Sep 27, 2004 |  BioCentury  |  Finance

Ebb & Flow

BioMarin's first announcement related to Orapred, the flagship of its new pediatrics focus, wasn't a great one, as the company expects no revenue contribution from the pediatric asthma drug in the second half. Moreover, there's...
07:00 , Sep 20, 2004 |  BC Extra  |  Financial News

Novagali completes EUR 14.2M series B

Drug delivery company Novagali (Evry, France) raised EUR 9.2 million ($11.2 million) in a second closing of series B round, bringing the total raised in the round to EUR 14.2 million ($17.3 million). New investors...
07:00 , Aug 9, 2004 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Gamida Cell Ltd. Jerusalem, Israel Technology: Stem cell expansion for hematopoietic stem cell therapeutics Disease focus: Leukemia, myocardial infarction (MI), diabetes Clinical status: Phase I/II Founded: 1998 by Tony Peled and Hadassah Hospital Corporate partners:...
07:00 , May 24, 2004 |  BioCentury  |  Finance

Top European B rounds

Top European B rounds Company Raised Date Focus Location Investors Notes Addex $39.0 5/17/04 Neurology Switzerland TVM Techno Venture Management; PolyTechnos; Bio*One Capital; Vinci Capital; Initiative Capital; Fulcrum Pharma; Index Ventures; Sofinnova Partners Arrow $34.9...
07:00 , Apr 19, 2004 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Targacept Inc. Winston-Salem, N.C. Technology: Neuronal nicotinic receptor (NNR) chemistry and biology Disease focus: Neurology Clinical status: Phase II Founded: 2000 as a spinout from R.J. Reynolds Tobacco Co. University collaborators: Wake Forest University School...